ArticleScientific reports2025
Lamina cribrosa curvature depth and index as novel parameters in Graves' ophthalmopathy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Deep Optic Nerve Head Structural Alterations in Adults with Cystic Fibrosis.Journal of clinical medicine · 2026Article
- Differences of the lamina cribrosa between primary open angle glaucoma and non-pathologic high myopia.International journal of ophthalmology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate lamina cribrosa (LC) parameters, macular ganglion cell layer thickness (GCLT) and peripapillary retina nerve fiber layer thickness (RNFLT) in Graves' Ophthalmopathy (GO) patients using spectral domain optical coherence tomography (SD-OCT). Seventy GO patients and 70 healthy subjects were included in the study. LC thickness (LCT), LC depth (LCD), LC curvature depth (LCCD), LC curvature index (LCCI) measurements, peripapillary RNFLT and macular GCLT were evaluated with SD-OCT, and proptosis was evaluated with Hertel exophthalmometer. Clinical activity was assessed using the clinical activity score (CAS). Disease severity was evaluated according to the European Group on Graves Orbitopathy (EUGOGO) stage. SD-OCT revealed significant differences in the LC morphology between the affected and control groups. LCT was significantly decreased in the GO group (236.7 ± 37.1 μm) compared to the control group (276.1 ± 36.3 μm) (p < 0.001). Median LCCD was significantly higher in the patient group [95.5 (80.5-127.5) µm] than in the control group [78 (66-90.25) µm] (p < 0.001). LCCI was 6.08 (4.7-7.5) in the GO group and 4.9 (4.3-5.6) in the control group. The difference between the two groups regarding LCCI was statistically significant (p < 0.001). The mean LCD, central foveal GCLT, peripapillary global RNFLT and central foveal thickness were not significantly different between the two groups (p = 0.124, p = 0.536, p = 0.226 and p = 0.958, respectively).LC morphology may change in patients with GO. LCT, LCCI and LCCD showed a good ability to differentiate GO from healthy controls. Therefore, they can be used as supporting parameters for diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.